🔍

Medico Remedies Limited (MEDICO)

₹22.03 +0.55% last close, 16 Oct

📊 NSE: MEDICO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 23 Sep 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Medico Remedies' revenue was ₹69.4 Cr (+81.4% year on year, +22.2% on the previous quarter), and net profit ₹2.5 Cr (+38.5% year on year); the operating margin was 4.8%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹69.4	+81.4%	+22.2%
Operating profit	₹3.3	+16.8%	-53.8%
Net profit	₹2.5	+38.5%	-57.0%
EPS (₹)	0.30	+36.4%	-57.7%
Operating margin	4.8%	—	—

Full quarterly financials → Results calendar →

MEDICO delivery percentage and bulk deals

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 74.16% of the MEDICO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 58.35%. That is higher than usual for this stock. Turnover was only ₹34 lakh, so a handful of trades can move this figure. Volume was 0.2 times its average, well below normal. It closed at a price band (circuit) on 1 session in about the last 20. 1 bulk or block deal was reported in MEDICO in the last 60 days: ₹1 Cr sold, none bought.

74.16%Delivery, 16 Oct

58.35%Own 20-session average

0.2×Volume vs its average

₹22.03NSE close · +0.55%

Delivery in the last 5 sessions: 55.3% · 57.5% · 54.6% · 59.8% · 74.2%

Date	Side	Counterparty	Value	Price	Quantity	Type
25 Sep	Sell	Savitriben Mahendrakumar Shah	₹1.19 Cr	₹27.22	437,647	Bulk

Delivery across the market →Circuit stocks →All bulk and block deals →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Medico Remedies AGM: All 7 Resolutions Passed, Approving Re-appointments and Remuneration Hikes

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 23 Sep 2026, 04:33 PM

Medico Remedies reported the voting results of its 32nd Annual General Meeting held on September 22, 2026, where all 7 resolutions were approved by requisite majority. Key approvals included the re-appointment of Mr. Rishit Mehta as Whole-time Director and Mr. Haresh Mehta as Chairman & Whole-Time Director. Additionally, shareholders approved remuneration increases for MD Mr. Harshit Mehta, Regulatory Deputy Manager Ms. Shweta Harshit Mehta, and professional fee revisions for Ms. Priyal Rishit Mehta. Across the resolutions, total promoter and public participation approved proposals with near-unanimous valid votes cast, although public participation was low with only 167,626 to 181,626 public shares voted.

All 7 resolutions passed by requisite majority at the 32nd AGM held on September 22, 2026
Resolution 5 (MD remuneration hike) passed with 97.69% votes in favour (35,74,804 votes) and 2.31% against (84,597 votes)
Re-appointment of Whole-Time Directors Haresh Mehta and Rishit Mehta approved
Record date was September 15, 2026, with a total of 16,439 shareholders
Total shares voted on financial statements adoption stood at 5,11,04,771 out of 8,29,84,000 shares (61.58% turnout)

💡 Track the upcoming quarterly financial disclosures to see the operational impact of remuneration and fee increases on overall employee/administrative costs.

Medico Remedies Sets Book Closure From Sept 16 to Sept 22, 2026 for 32nd AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Aug 2026, 05:04 PM

Medico Remedies Limited has announced the closure of its Register of Members and Share Transfer Books from Wednesday, September 16, 2026, to Tuesday, September 22, 2026 (both days inclusive). The closure is scheduled ahead of the company's 32nd Annual General Meeting (AGM) to be held on September 22, 2026, at 4:00 PM via video conferencing. The total paid-up equity capital mentioned is Rs 16.60 crore (Rs 16,59,68,000).

Book closure period: September 16, 2026 to September 22, 2026 (both days inclusive)
32nd AGM scheduled for Tuesday, September 22, 2026, at 4:00 PM via VC/OAVM
Paid-up equity share capital stands at Rs 16,59,68,000

💡 Shareholders should note the AGM date (Sept 22, 2026) to review the annual report and participate in AGM voting resolutions.

Medico Remedies Submits FY26 Annual Report; 32nd AGM Scheduled for September 22, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Aug 2026, 04:47 PM

Medico Remedies Limited has published its Annual Report for FY 2025-26 and scheduled its 32nd Annual General Meeting (AGM) for September 22, 2026. Key agenda items include the adoption of FY26 financial statements and the re-appointment of Mr. Haresh Mehta (Chairman & WTD) and Mr. Rishit Mehta (WTD) for a three-year tenure effective September 18, 2026, at a basic salary not exceeding Rs 7.5 lakh per month each plus performance bonus. The filing also presents audited financial statements and standard statutory disclosures.

32nd Annual General Meeting scheduled for September 22, 2026, via Video Conferencing.
Proposed re-appointment of Mr. Haresh Mehta as Chairman & WTD for 3 years (Sep 18, 2026 to Sep 18, 2029).
Proposed re-appointment of Mr. Rishit Mehta as Whole-Time Director for 3 years with basic salary up to Rs 7,50,000 per month.
Proposed bonus of 9% of annual remuneration for both Whole-Time Directors.
FY26 reporting reflects a Net Profit Ratio of 6.35% (vs 6.69% prior) and ROCE of 20% (vs 18% prior).

💡 Track shareholder voting results post the AGM on September 22, 2026, and monitor upcoming quarterly operational performance and export demand.

81% Revenue Growth in Q1 FY27; Medico Remedies Reports ₹69.40 Cr Revenue

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 05:47 PM

Medico Remedies Limited reported a strong performance for Q1 FY27, with revenue from operations surging 81.4% YoY to ₹69.40 cr. Net profit grew 38.5% YoY to ₹2.52 cr, although margins appear slightly compressed compared to the top-line growth. A significant shift was observed in the sales mix, with domestic sales jumping to ₹26.34 cr from just ₹2.74 cr in the preceding quarter. The board also approved the re-appointment of key promoter-directors and an increase in the Managing Director's remuneration.

Revenue from operations increased by 81.4% YoY to ₹69.40 cr from ₹38.25 cr in Q1 FY26.
Net profit for the quarter rose 38.5% YoY to ₹2.52 cr compared to ₹1.82 cr in the same period last year.
Domestic sales saw a massive sequential jump to ₹26.34 cr in Q1 FY27 from ₹2.74 cr in Q4 FY26.
Export sales moderated to ₹42.70 cr in Q1 FY27 from ₹53.64 cr in Q4 FY26, now representing 61.5% of total sales.
Board approved the re-appointment of Chairman Haresh Mehta and WTD Rishit Mehta for 3-year terms starting September 18, 2026.

💡 Investors should monitor the sustainability of the sudden surge in domestic sales and whether this shift from an export-heavy model (previously 95% exports) impacts long-term operating margins.

₹13.38 Cr Order Win: Medico Remedies to Supply Dominican Republic Government

🟢 POSITIVE ⭐ 7/10

OTHER 📅 05 Aug 2026, 04:41 PM

Medico Remedies has secured a government supply order from PROMESE/CAL, Dominican Republic, valued at approximately ₹13.38 Crores (USD 1.41 million). The contract involves the supply of tablets, capsules, and dry syrups to the National Public Health System. The company is required to complete the entire order within a 3-month timeframe. This win is material, representing roughly 22.8% of the company's Dec 2025 quarterly revenue of ₹58.68 Crores.

Order value of USD 1,406,450, equivalent to approximately ₹13.38 Crores
Full order execution mandated within a short 3-month window
Client is PROMESE/CAL, the centralized health logistics agency for the Dominican Republic
Product scope includes tablets, capsules, and dry syrups
Order represents ~22.8% of the company's Dec 2025 quarterly revenue

💡 Watch for the impact on the next two quarters' revenue and margins, especially considering the company's 95% export exposure and potential FX volatility during the 3-month execution period.

Medico Remedies Announces Trading Window Closure from July 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jun 2026, 05:34 PM

Medico Remedies Limited has announced the closure of its trading window for all insiders and designated persons starting July 1, 2026. This action is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results. The window will remain closed until 48 hours after the unaudited financial results for the quarter ended June 30, 2026, are made public. This is a routine administrative filing and does not impact the company's fundamental operations.

Trading window closure effective from July 1, 2026
Restriction applies to all Insiders, Designated Persons, and their immediate relatives
Window to remain closed until 48 hours post-declaration of Q1 FY2026-27 results
Company reported Dec 2025 quarterly revenue of ₹58.68 Cr

💡 Investors should wait for the official announcement of the board meeting date to know when the Q1 FY2026-27 results will be released.

₹42 Cr Bank Facilities Rated; CRISIL Reaffirms BBB-/Stable for Medico Remedies

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 29 Jun 2026, 06:10 PM

CRISIL Ratings has reaffirmed Medico Remedies Limited's long-term rating at 'CRISIL BBB-/Stable' and short-term rating at 'CRISIL A3'. Notably, the total rated bank facilities have been enhanced to ₹42 crore from the previous ₹19 crore, providing the company with additional credit headroom. With a current debt of ₹19 crore against a net worth of ₹76 crore (D/E of 0.25), the company maintains a conservative leverage profile. The enhancement in rated facilities likely supports the company's stated strategy to expand its manufacturing footprint and product range in export markets.

Total bank loan facilities rated increased to ₹42 crore from ₹19 crore
Long-term rating reaffirmed at CRISIL BBB-/Stable for ₹19 crore term loan and ₹18 crore packing credit
Short-term rating reaffirmed at CRISIL A3 for ₹5 crore non-fund based facilities
Company maintains a healthy ROCE of 23.0% and a low Debt/Equity ratio of 0.25
95% of sales are derived from exports, making the company sensitive to foreign exchange fluctuations

💡 Investors should monitor the utilization of the newly enhanced ₹42 crore credit limit and its impact on interest costs and the working capital cycle, particularly given the risk of GCA days stretching beyond 200 days.

Medico Remedies Fined ₹1.13 Lakh by NSE and BSE for Regulatory Non-Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 03 Jun 2026, 06:32 PM

Medico Remedies Limited has paid a total fine of ₹1,13,280 (₹56,640 each to NSE and BSE) for non-compliance with Regulation 6(1) of SEBI (LODR) Regulations. The violation occurred during the period from January 1, 2026, to February 17, 2026, regarding the appointment of a qualified Company Secretary as Compliance Officer. The company has since rectified the issue and has been compliant since February 18, 2026. Management has stated that this penalty has no material impact on the company's financial or operational performance.

Fined ₹56,640 each by NSE and BSE (Total ₹1,13,280 inclusive of GST) for Regulation 6(1) non-compliance.
The non-compliance period was identified between January 1, 2026, and February 17, 2026.
The company received the SoP notices on May 20, 2026, and paid the fines on May 25, 2026.
Full compliance with the regulation was restored effective February 18, 2026.
Management confirmed no material impact on financials, operations, or other activities.

💡 Investors should treat this as a minor administrative lapse. No action is required as the fine is negligible and the compliance issue has already been resolved.

Medico Remedies FY26 Net Profit Rises 30% to ₹13.13 Cr; Revenue Up 37% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 21 May 2026, 06:30 PM

Medico Remedies Limited reported a robust financial performance for the fiscal year ended March 31, 2026. Annual revenue from operations grew significantly by 36.7% to ₹206.38 crore, while net profit increased by 30% to reach ₹13.13 crore. The fourth quarter (Q4 FY26) also showed strong momentum with a net profit of ₹5.86 crore compared to ₹4.34 crore in the corresponding quarter of the previous year. The company's auditors have issued a clean, unmodified opinion on these results.

Annual revenue from operations increased to ₹20,637.73 lakhs in FY26 from ₹15,094.06 lakhs in FY25.
Net profit for the full year grew 30% YoY to ₹1,312.52 lakhs.
Q4 FY26 revenue stood at ₹5,680.77 lakhs, representing a 37.5% growth over Q4 FY25.
Earnings Per Share (EPS) improved to ₹1.58 for FY26 from ₹1.22 in the previous fiscal year.
Total expenses for the year rose to ₹19,425.12 lakhs, driven largely by a 33% increase in material costs.

💡 Investors should take note of the company's strong growth trajectory in both revenue and profitability. While the growth is impressive, monitoring the rising 'Other Expenses' and material costs will be crucial to ensure margin stability in future quarters.

Medico Remedies Fined ₹1.27 Lakh by NSE and BSE for Regulatory Non-Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 16 Apr 2026, 05:42 PM

Medico Remedies Limited has been penalized by both the NSE and BSE for non-compliance with Regulation 6(1) of SEBI (LODR) Regulations, which typically pertains to the appointment of a Compliance Officer. The company was fined ₹63,720 by each exchange, totaling ₹1,27,440. Although the company sought a waiver for these penalties, the applications were rejected by BSE on March 5, 2026, and by NSE on April 10, 2026. The company has already paid the fines and confirmed it has been in compliance with the regulation since February 18, 2026.

Penalty of ₹63,720 (inclusive of GST) levied by both NSE and BSE for Regulation 6(1) non-compliance.
Waiver applications filed by the company were rejected by BSE on March 5 and NSE on April 10, 2026.
Total penalty amount of ₹1,27,440 has been paid by the company as of February 24, 2026.
Company achieved compliance with the specific SEBI regulation effective February 18, 2026.
Management confirms no material impact on financial or operational activities due to this action.

💡 Investors should view this as a minor administrative lapse with negligible financial impact. No immediate action is required, though consistent regulatory compliance should be monitored.

Medico Remedies Faces Rs 1.27 Lakh Penalty from NSE and BSE for Regulatory Non-Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Feb 2026, 05:48 PM

Medico Remedies Limited has received notices from both NSE and BSE for alleged non-compliance with Regulation 6(1) of SEBI (LODR) Regulations. The exchanges have levied a penalty of Rs. 63,720 each, totaling approximately Rs. 1.27 lakh including GST. The company received these notices on February 20, 2026, and has subsequently filed waiver applications with both exchanges on February 24, 2026. Management states there is no material impact on the company's financial or operational activities due to this development.

NSE and BSE levied a penalty of Rs. 63,720 each (including GST) for Regulation 6(1) non-compliance.
The total financial penalty involved is approximately Rs. 1.27 lakh.
Notices were received on February 20, 2026, and waiver applications were filed on February 24, 2026.
The company states there is no material impact on financials, operations, or other activities.

💡 This is a minor regulatory matter with negligible financial impact; no immediate action is required from investors. However, it is advisable to monitor for any recurring compliance issues that might suggest internal governance weaknesses.

Medico Remedies Appoints Vidhi Ankit Shah as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 18 Feb 2026, 04:14 PM

Medico Remedies Limited has officially appointed Ms. Vidhi Ankit Shah as the Company Secretary and Compliance Officer, effective February 18, 2026. This appointment fills a Key Managerial Personnel (KMP) position as required under Section 203 of the Companies Act, 2013. Ms. Shah brings over 9 years of professional experience in handling secretarial compliances for both listed and unlisted companies. The board approved this move following the recommendation of the Nomination and Remuneration Committee to ensure continued regulatory adherence.

Appointment of Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer effective Feb 18, 2026
Appointee possesses over 9 years of experience in secretarial and regulatory compliance functions
Designated as Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013
The decision was finalized during the Board Meeting held on February 18, 2026

💡 This is a routine administrative appointment to ensure regulatory compliance and does not impact the company's fundamental value. No immediate action is required from investors.

Medico Remedies Approves Unaudited Financial Results for Q3 FY26

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 12 Feb 2026, 06:00 PM

Medico Remedies Limited held a board meeting on February 12, 2026, to approve the unaudited standalone financial results for the quarter and period ended December 31, 2025. The meeting was conducted efficiently, lasting only 30 minutes from 5:00 PM to 5:30 PM. The board also reviewed and approved the Auditors' Limited Review Report for the same period. This filing marks the completion of the company's regulatory requirements for the third quarter of the 2025-26 fiscal year.

Board approved Unaudited Standalone Financial Results for the quarter ended December 31, 2025.
The meeting was held on February 12, 2026, and concluded within 30 minutes.
Auditors' Limited Review Report was formally considered and approved by the board.
Compliance confirmed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements.

💡 Investors should examine the detailed financial tables to evaluate revenue growth and margin performance compared to previous quarters. Monitor the stock for any price movement following the formal release of these earnings figures.

Medico Remedies Approves Unaudited Financial Results for Quarter Ended Dec 31, 2025

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 12 Feb 2026, 05:47 PM

Medico Remedies Limited has officially approved its unaudited standalone financial results for the quarter ended December 31, 2025. The board meeting was held on February 12, 2026, and concluded within 30 minutes, signifying a routine regulatory approval process. While the specific financial figures were not detailed in the summary letter, the announcement confirms the completion of the limited review by auditors. Investors should now look to the detailed financial tables for specific revenue and margin performance.

Board approved unaudited standalone financial results for the quarter ended December 31, 2025.
The board meeting was conducted on February 12, 2026, from 5:00 P.M. to 5:30 P.M.
The results were submitted along with the Auditors’ Limited Review Report as per SEBI regulations.
The filing covers the performance for the third quarter of the 2025-26 fiscal year.

💡 Investors should examine the full financial statements for specific growth in net profit and revenue. Compare the Q3 performance against previous quarters to assess the company's operational trajectory.

Medico Remedies Bags ₹37.18 Crore Order from UP Medical Supplies Corporation

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 27 Jan 2026, 11:52 AM

Medico Remedies Limited has secured a significant domestic supply order worth approximately ₹37.18 crore from the Uttar Pradesh Medical Supplies Corporation Limited. The contract involves the supply of multiple drugs to the Government of Uttar Pradesh's centralized distribution entity. The company is expected to complete the full supply of the order by October 31, 2026. This government contract provides strong revenue visibility for the company over the next 20 months.

Total order value is ₹37,17,62,439 (approximately ₹37.18 crore)
Contract awarded by Uttar Pradesh Medical Supplies Corporation Limited, a GoUP entity
The order involves the supply of multiple drugs for state-wide distribution
Project completion timeline is set for October 31, 2026

💡 Investors should view this as a positive development for revenue growth and monitor the company's ability to maintain margins on government-tendered contracts. Watch for timely execution updates as the October 2026 deadline approaches.

View All MEDICO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates as a single operating segment (pharmaceutical formulations). Total revenue grew by 6.2% from INR 145 crore in FY2023-24 to INR 154 crore in FY2024-25. Revenue for the half-year ended September 30, 2025, reached INR 90.03 crore compared to INR 73.94 crore in the previous year's corresponding period, representing a 21.7% increase.

Geographic Revenue Split

The company is heavily export-oriented, with more than 95% of revenue generated from international markets. For the quarter ended September 30, 2025, international sales were INR 46.75 crore (89.6% of quarterly revenue) while domestic sales were INR 5.43 crore (10.4% of quarterly revenue). Key markets include Honduras, Dominican Republic, Nigeria, and the Philippines.

Profitability Margins

Operating Profit Margin improved from 8% in FY2023-24 to 9% in FY2024-25. Net Profit Margin increased from 6% to 7% in the same period. For the half-year ended September 30, 2025, the company reported a net profit of INR 4.39 crore, a 39.8% increase from INR 3.14 crore in the previous year's half-year period.

EBITDA Margin

EBITDA margin was reported at 7% in Q2 FY2024 and 8% in Q1 FY2024. Historical EBITDA margins have fluctuated between 4.7% and 11.5% over the last four fiscals due to raw material price volatility and forex fluctuations.

Capital Expenditure

The company has invested in a new manufacturing unit for ointments and creams. Capital work-in-progress (CWIP) stood at INR 0.47 crore as of September 30, 2025, compared to INR 0.36 crore as of March 31, 2025. Construction has also commenced on a new factory for beta-lactam tablets, capsules, dry syrups, and injections to scale operations.

Credit Rating & Borrowing

CRISIL Ratings maintains a 'Stable' outlook. The company exhibits a comfortable capital structure with a gearing ratio of 0.2 times and a total outside liabilities to adjusted networth (TOL/ANW) ratio of 0.9 times as of March 31, 2025. Interest coverage ratio is healthy at 20.35 times for FY2024-25.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed, but raw materials represent a significant cost component, with 15-20% of requirements being imported. Fluctuations in these costs directly impact the operating margins, which have historically ranged from 4.7% to 9.5%.

Import Sources

The company imports 15-20% of its raw materials. While specific countries are not listed, the management notes a strategy to de-risk dependency on China for key raw materials in line with industry trends.

Capacity Expansion

Current operations involve a diversified portfolio of 300 products. Expansion includes a new manufacturing unit for ointments and creams and a planned facility for beta-lactam products (Amoxicillin with potassium clavulanate) to drive future turnover growth.

Raw Material Costs

Raw material costs are susceptible to high volatility. While the company attempts to pass on price increases to customers, there is typically a time lag that affects short-term profitability.

Manufacturing Efficiency

The company is transitioning to more efficient manufacturing approaches and new technologies to remain competitive in pharmerging markets.

Logistics & Distribution

Distribution is primarily focused on exports (>95%), making the company highly sensitive to global shipping costs and international trade regulations.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the production of an additional range of products, specifically Amoxicillin with potassium clavulanate tablets and dry syrups. The company is also expanding its manufacturing footprint with a new beta-lactam facility and targeting 'untouched' sectors in international markets to leverage the 3-6% projected global market CAGR.

Products & Services

Pharmaceutical formulations including anti-biotics, anti-infectives, antipyretics, analgesics, anti-diabetics, diuretics, antimalarials, NSAIDS, antiretrovirals, anti-ulcer drugs, antacids, and external preparations like creams and ointments.

New Products/Services

New product launches include Amoxicillin with potassium clavulanate tablets and dry syrups, which are expected to provide substantial growth in sales turnover and profitability.

Market Expansion

Targeting expansion in pharmerging markets and increasing penetration in existing regions like Honduras, Nigeria, and the Philippines.

🌍 External Factors

Industry Trends

The industry is shifting toward speciality products in developed markets and volume growth in pharmerging markets. There is a global trend of de-risking supply chains away from China for active pharmaceutical ingredients (APIs).

Competitive Landscape

Competes with both large-scale Indian pharmaceutical companies and local players in export markets. Scale is currently 'moderate,' which limits bargaining power.

Competitive Moat

The company's moat is built on the promoters' 40+ years of experience and a diversified portfolio of 300+ products. This prevents over-reliance on any single drug (no product >10% of sales), though it lacks the scale of major competitors.

Macro Economic Sensitivity

Highly sensitive to global healthcare spending and per capita income in pharmerging markets. The Indian pharma industry is expected to grow 6-8% YoY in FY25.

Consumer Behavior

Increasing healthcare awareness and an aging global population are driving higher demand for chronic and acute therapeutic medicines.

Geopolitical Risks

Trade barriers or regulatory changes in key export markets (Nigeria, Philippines, etc.) could disrupt 95% of the revenue stream.

⚖️ Regulatory & Governance

Industry Regulations

Operations must comply with WHO-GMP standards for manufacturing and IND AS for financial reporting. The company is subject to various drug control regulations in every country it exports to.

Taxation Policy Impact

The company provided for INR 1.31 crore in tax expenses for the half-year ended September 30, 2025, on a profit before tax of INR 5.91 crore (effective tax rate of approximately 22.2%).

⚠️ Risk Analysis

Key Uncertainties

Volatility in raw material prices and foreign exchange rates are the primary uncertainties, potentially impacting operating margins by 2-4% based on historical volatility ranges.

Geographic Concentration Risk

Extremely high geographic concentration in exports, with 95% of revenue coming from outside India.

Third Party Dependencies

Dependency on external suppliers for 15-20% of raw materials via imports and a growing dependency on the top 5 customers who now control 56% of revenue.

Technology Obsolescence Risk

The company identifies dependency on telecommunication and information technology systems as a risk factor in its caution statement.

Credit & Counterparty Risk

Gross Current Asset (GCA) days are high at 170-180 days, indicating a long wait time for receivables and potential credit risk if export customers delay payments.